Source comparison
Best ARA-290 Dosage for Neuropathy: Protocol Comparison
Sarcoidosis-associated SFN 4mg SC daily 28 days Inflammatory cytokine reduction (TNF-α, IL-6) via IRR signalling +0.73 fibers/mm IENFD; 29% pain score reduction Gold standard for inflammatory small fiber neuropathy. Lower dose minimises injection site reaction
This comparison does not assign a generated winner or score.
- Sarcoidosis-associated SFN
- 4mg SC daily
- 28 days
- Inflammatory cytokine reduction (TNF-α, IL-6) via IRR signalling
- +0.73 fibers/mm IENFD; 29% pain score reduction
- Gold standard for inflammatory small fiber neuropathy. Lower dose minimises injection site reactions while achieving structural nerve regeneration
- Diabetic polyneuropathy (Type 1/2)
- 6–8mg SC daily
- 21–28 days
- Dual anti-inflammatory + microvascular protection; oxidative stress reduction
- +1.2mm/mm² CNFL at 8mg; 31% pain reduction
- Higher dose necessary for metabolic neuropathy. Microvascular component requires greater receptor occupancy than inflammatory alone
- Idiopathic small fiber neuropathy
- IRR-mediated neuroprotection; axonal repair signalling
- Variable IENFD response; 18–24% symptom improvement
- Conservative starting dose appropriate given heterogeneous etiology. Some cases are subclinical autoimmune and respond robustly, others show minimal change
- Chemotherapy-induced peripheral neuropathy
- 6mg SC daily (investigational)
- Mitochondrial protection; reduction of platinum-induced axonal injury
- Preliminary data only. Nerve conduction velocity stabilisation observed
- Promising early results but limited human trial data. Mechanism suggests efficacy but optimal dose unconfirmed
- This comparison reflects published trial data through 2026. The 4mg dose for sarcoidosis SFN is the most rigorously validated protocol. Diabetic polyneuropathy dosing shows clear dose-response relationship but optimal duration (28 days vs longer cycles) remains under investigation. Idiopathic SFN presents diagnostic complexity. Response varies because 'idiopathic' often masks undiagnosed autoimmune or metabolic triggers. CIPN protocols are investigational; extrapolating from diabetic neuropathy trials suggests 6mg as a reasonable starting point pending Phase 3 data.